Search
for
Sort by
Research 121–150 of 1000+
- Wnt Signaling in Skin Development, Homeostasis, and Disease
- Cutaneous complications of chemotherapeutic agents
- Exosomes for repair, regeneration and rejuvenation
- Control of hair follicle cell fate by underlying mesenchyme through a CSL–Wnt5a–FoxN1 regulatory axis
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Clinical and biological impact of the exposome on the skin
- Costunolide—A Bioactive Sesquiterpene Lactone with Diverse Therapeutic Potential
- Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas
- Dermatologic Manifestations of Human Immunodeficiency Virus Infection
- Drug-induced acne
- The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells
- Microneedle-Based Approaches for Skin Disease Treatment
- Endocrine-skin interactions
- Acquired scalp alopecia. Part I: A review
- Cicatricial (Scarring) Alopecias
- Differences in Expression of Specific Biomarkers Distinguish Human Beard from Scalp Dermal Papilla Cells
- Acquired scalp alopecia. Part II: A review
- Dermoscopy of scalp tumours: a multi‐centre study conducted by the international dermoscopy society
- Dermoscopy Research—An Update
- Parkinson's disease and skin
- Medication-Induced Repigmentation of Gray Hair: A Systematic Review
- MicroRNA in skin diseases
- iNKT cells ameliorate human autoimmunity: Lessons from alopecia areata
- Field Cancerization: From Molecular Basis to Selective Field-Directed Management of Actinic Keratosis
- A missing piece: the spiny mouse and the puzzle of menstruating species
- Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection
- Epimorphic regeneration in mice is p53-independent
- An Update on Drug-Induced Pigmentation
- Medical Treatment of Hepatocellular Carcinoma: Any Progress?
- Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects